^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + LRP1B mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, Low density lipoprotein-related protein 1B, LRPDIT, LRP1B, LDL receptor related protein 1B, Low-density lipoprotein receptor-related protein 1B, LRP-1B
    Entrez ID:
    1956; 53353
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3ms
    An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development. (PubMed, J Cancer)
    Mutations in EGFR and LRP1B could potentially establish an immune niche that fosters tumor growth. PAMs in LUAD may accelerate disease progression by promoting T cell differentiation into an exhausted state.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • LRP1B (LDL Receptor Related Protein 1B) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • EGFR mutation • TMB-H • LRP1B mutation • LRP1B mutation + TMB-H • EGFR mutation + LRP1B mutation
    10ms
    Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials (IASLC-WCLC 2023)
    In this study, the impact of EGFR co-mutations on ICI efficacy was analyzed. The data were obtained from OAK trial (a randomized, open-label, phase 3 trial) and POPLAR trial (a randomized, open-label, phase 2 trial), in which advanced NSCLC patients receiving either second/third-line atezolizumab or docetaxel [5, 6]. Our study suggested that EGFR co-mutation patterns do have a substantial impact on the efficacy of ICIs, with varying effects of varying co-mutation patterns, such that patients with co-mutations of EGFR and LRP1B or FAT3 significantly benefited more from ICIs.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • LRP1B (LDL Receptor Related Protein 1B) • FAT3 (FAT Atypical Cadherin 3)
    |
    PD-L1 expression • TP53 mutation • EGFR mutation • EGFR mutation + LRP1B mutation
    |
    Tecentriq (atezolizumab) • docetaxel